CQC has begun incorporating AI governance into inspections. ICO has enforcement powers over health data. MHRA regulates AI tools that meet the definition of a medical device. The governance landscape is fragmented, evolving rapidly, and largely the responsibility of the organisation deploying the tool.
NHS England’s AI strategy is explicit: AI has the potential to transform healthcare delivery, improve diagnostic accuracy, and reduce administrative burden. The strategy is ambitious and the investment is real. What the strategy cannot do is govern AI use at the level of an individual trust, GP surgery, or private healthcare provider. That work sits with you.
The CQC has already begun incorporating AI governance into its inspection framework. The ICO has enforcement powers over health data. NHS Digital guidelines on data sharing and secondary use apply to AI systems processing patient records. The MHRA regulates AI tools that meet the definition of a medical device. The governance landscape is fragmented, evolving rapidly, and largely the responsibility of the organisation deploying the tool.
AI tools that assist diagnosis, triage, or treatment recommendations are not neutral. They encode the biases of their training data. An AI trained predominantly on data from certain demographic groups may perform worse for others. That is a patient safety issue and a potential Equality Act issue simultaneously.
Special category data under GDPR — which includes health data — attracts the highest protections. Processing it with AI requires a lawful basis, a DPIA in most cases, and explicit consideration of data minimisation. “Legitimate interests” does not apply to special category data.
AI tools that interpret imaging, analyse pathology results, or generate clinical recommendations may qualify as medical devices under UK MDR 2002 (as amended). Using unregistered AI tools in clinical contexts — even informally — creates regulatory exposure for the organisation.
Healthcare staff using general AI tools to draft letters, summarise notes, or research clinical questions creates uncontrolled data flows and potential quality risks. This is happening. A governance framework that acknowledges and channels it is more effective than a prohibition nobody follows.
NHS AI strategy in practice. CQC’s evolving approach to AI in inspections. MHRA classification of AI tools. ICO guidance on health data and AI. Understanding which regulations apply to which tools.
We work through your current or planned AI tool usage — clinical decision support, administrative AI, staff-used consumer tools — and classify each by clinical risk, data risk, and regulatory exposure.
DPIA requirements for AI processing health data. Lawful basis analysis. Data processing agreements with AI vendors. Patient transparency obligations. Data minimisation in AI workflows.
Performance monitoring obligations for clinical AI. Bias auditing: what questions to ask vendors. Human oversight requirements. Incident reporting pathways when AI tools may have contributed to a patient safety event.
Drafting your AI use policy for clinical and administrative contexts. Staff training approach. Patient transparency — how and when to inform patients of AI involvement in their care.
| Use case | Efficiency gain | Primary risk |
|---|---|---|
| AI triage and symptom checking | Capacity, speed | Demographic performance bias, patient safety |
| Clinical letter drafting | Admin efficiency | Accuracy, data handling, patient safety |
| Diagnostic imaging AI | Accuracy, speed | MHRA compliance, over-reliance |
| Appointment booking AI | Efficiency | Equity of access, data handling |
| Coding and billing AI | Revenue, speed | Coding accuracy, fraud risk |
| Clinical decision support | Consistency | Bias, over-reliance, liability |
We assess where you stand against your sector’s regulatory floor and identify your highest-priority governance gaps.
One hour with leadership. Sector-specific regulatory framework, immediate priority actions, the language to take this to the wider team.
Half or full day. Full risk mapping for your sector, governance protocols, AI use policy draft, and 30 days advisory access. The flagship engagement.
Multi-site, network, and group pricing available on request.
A CE or UKCA mark confirms the device meets regulatory requirements at the point of approval. It does not govern how you implement, monitor, and audit the tool in your specific clinical environment. The organisation deploying a medical AI device has ongoing obligations: ensuring staff are trained, monitoring performance in your patient population, reporting adverse events, and maintaining records of use.
Traditional IG frameworks cover data handling, access controls, and incident management. They were designed before AI tools became mainstream clinical or administrative infrastructure. AI introduces additional considerations: algorithmic bias, model performance monitoring, explainability of AI-assisted decisions, and the specific legal basis questions around AI processing of special category data.
Staff are using AI tools — legitimately, to try to do their jobs better under significant pressure. A blanket prohibition is unenforceable and may reduce safety if it pushes usage further underground. Our approach is to create a clear, permissive framework that governs which tools can be used and how, so staff can use AI efficiently without creating uncontrolled regulatory exposure.
Tell us what AI tools your organisation is using or evaluating and we’ll give you an honest assessment of your governance readiness. No sales pressure. If your governance is sound, we’ll tell you.